Search All UT System Experts

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, David E. Gerber, Laura Q. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott J. Antonia

Research output: Contribution to journal › Article › peer-review

803 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study'. Together they form a unique fingerprint.

Medicine & Life Sciences